LRRK2 and Parkinson disease: After analyzing the Parkinson’s Progression Markers Initiative dataset, Bogacki et al. noted that LRRK2 mutation carriers showed highly elevated GPNMB levels in their CSF, higher than controls and still higher than people with idiopathic PD or PD linked to GBA mutation.